Sign in
Taking peoplePhase 4

Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology.

Key facts

Who runs it
Centre Hospitalier Universitaire De Toulouse
Where
France22 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 4
People taking part
1,164 people, planned
Started
2 Aug 2023
Expected to end
31 Dec 2029
Type of study
Interventional
Record updated
20 May 2026

Who can take part

Age
18 years to 64 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Nulliparous women aged 18 years or more
  • Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor
  • Singleton pregnancy
  • Evolutive pregnancy between 9 and 15 (+6 days) weeks of gestation
  • Women affiliated to a French Social Security Insurance or equivalent social protection
  • Written informed consent

Who cannot take part

  • Regular treatment with aspirin (including antiphospholipid syndrome)
  • Patient included in another drug study or another interventional study which could interfere with the results of the study
  • Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia)
  • Major fetal abnormality
  • Women protected by law

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluate the effect of aspirin 150mg daily initiated between 9 and 15(+6 days) weeks of gestation versus placebo in the prevention of preterm (<37 weeks of gestation) preeclampsia in nulliparous pregnant women after assisted reproductive technology.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology. APPART trial
Criteria questions
Built from 2022-500933-10-00, who can take part
Record updated
20 May 2026